Lidokain-Fluorescein Bausch & Lomb (Fluorescein Sodium, Lidocaine Hydrochloride)

Lidocaine hydrochloride blocks voltage‑gated sodium channels on sensory nerves, producing temporary loss of sensation on the eye surface. Fluorescein sodium adheres to damaged epithelial cells and fluoresces under cobalt‑blue light, creating a visible contrast that highlights corneal and conjunctival lesions for diagnostic evaluation.

The prescribed dose of Lidokain-Fluorescein is determined by the treating eye‑care professional based on the specific procedure or diagnostic need. The clinician will decide the volume and frequency of application appropriate for each patient.

Safety data for Lidokain-Fluorescein in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified health‑care provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lidokain-Fluorescein combines both anesthetic and staining functions in a single formulation, reducing the need for separate drops. Compared with using lidocaine alone, it offers diagnostic visualization, and compared with fluorescein alone, it provides temporary anesthesia, making it convenient for procedures that require both effects.

The product should be stored at room temperature below 25 °C, in its original container, protected from light and moisture. Avoid freezing or exposing the solution to extreme temperatures, and keep the vial tightly sealed when not in use.

Lidokain-Fluorescein is applied topically to the ocular surface as a drop or small volume of solution. The eye should be examined after a brief waiting period to allow anesthesia to take effect and the dye to stain the cornea, after which the clinician proceeds with the intended diagnostic or therapeutic procedure.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, significant corneal toxicity leading to persistent epithelial defects, and a marked increase in intra‑ocular pressure. Any signs of severe eye pain, vision loss, or systemic allergic symptoms require immediate medical attention.

Patients with a known hypersensitivity to lidocaine, fluorescein, or any component of the formulation should avoid using this product. It is also contraindicated in individuals with active severe ocular infections or inflammation where staining could mask disease progression.